Nanotechnology Now - Press Release: Nanoviricides, Inc. Presents at the International Conference on Nano-Materials and Applications (ICNAMA-2008) in India

Home > Press > Nanoviricides, Inc. Presents at the International Conference on Nano-Materials and Applications (ICNAMA-2008) in India

Abstract:
Dr. Diwan was Chief Guest at the Valedictory Ceremony

Nanoviricides, Inc. Presents at the International Conference on Nano-Materials and Applications (ICNAMA-2008) in India

WEST HAVEN, CT | Posted on December 15th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that Anil R. Diwan, Ph.D., Company President, was invited to present a lecture on nanomedicines and nanoviricides at the International Conference on Nano-Materials and Applications (ICNAMA-2008) held by Shivaji University, Kolhapur, India (SUK).

"We are entering an exciting era in medicine. Nanomedicine promises to provide medicines and diagnostics with effectiveness that earlier could only have been imagined. Previously incurable diseases such as cancer and HIV/AIDS may now be tackled effectively," he said, adding "A clear triumph of nanoviricide materials design and science is now evident. We have been able to develop both safe and highly effective drug candidates against many viral diseases. For example, for HIV/AIDS, NanoViricides, Inc. may now have a functional cure (as recently defined by Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases)." He also talked about the highly effective bird flu and influenza treatments being developed by the Company.

Dr. Diwan was also the Chief Guest of the Valedictory Ceremonies. In his speech at the closing ceremonies, he urged the participants that, "interdisciplinary cooperation is essential in the field of nanotechnology. Science and technology from diverse disciplines such as Physics, Chemistry, Electronics, Materials Science, as well as Biotechnology, Pharmacy, and Medicine need to come together if we are to realize the full potential of nanotechnology. The vast untapped talent of rural India should benefit from the exposure they have been fortunate to receive at this conference."

Professor A.A. Dange, Director of the Board of College and University Development, SUK, said he was pleased to have Dr. Diwan as the guest and hopes that the University can work together with him for development of the nanomedicine field in India. Professor M.M. Salunkhe, Vice-Chancellor, SUK, opened the Conference, commenting that he was very excited to bring this opportunity to expose rural Indian scientists from all over India to the highly specialized nanomaterials work being done at highly recognized Institutes and Companies in India as well as abroad.

The International Conference was organized jointly by the Departments of Chemistry and Physics of SUK, from Dec. 9th to Dec. 11th, and was attended by delegates from the USA, UK, Japan, France, Israel, the Netherlands, South Korea, Taiwan, Singapore, and Thailand, among other countries.

About Shivaji University (www.unishivaji.ac.in)

Shivaji University, established in 1962, today has a student strength of well over 200,000 in 32 post-graduate research departments on a beautiful sprawling campus of 849 acres in Kolhapur, and 214 affiliated colleges distributed across southern Maharashtra. The SUK Department of Physics ranks 6th in the Materials Science research among Indian Universities. The department is first in India in aerogels research, and is the first in the world in producing super-hydrophobic and flexible aerogels. The department of Chemistry is recognized by major Indian pharmaceutical industry as a source for highly skilled researchers.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: